AR and prostate cancer: Collectively, these data indicate that although both BPA and DHT can activate mutant AR and resultant cellular proliferation in prostate cancer cells, each agent induces a unique molecular signature, wherein genetic profiles induced by mitogenic doses of DHT or BPA showed both overlapping (e.g., PSA and ERβ) and divergent (e.g., FKBP5, WISP3) responses.